A PILOT STUDY OF P-2647, A NEW BENZOQUINOLIZINE DERIVATIVE EMPLOYED AS A PSYCHOTHERAPEUTIC AGENT IN 44 CASES OF OVERT ANXIETY
Abstract
P-2647, a new benzoquinolizine derivative, is structurally related to reserpine and tetrabenazine. It appears to possess unique ability to suppress conditioned avoidance behaviour without releasing central amines.
In this pilot study, P-2647 was administered to 44 anxious patients. Of these, 39 reported definite and significant reduction in anxiety. With the exception of mild sedation, no side effects were reported.
The results suggest that this new benzoquinolizine possesses a degree of psychotherapeutic activity and safety that makes it worthy of further investigation.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
